Efficacy and Safety of Telmisartan and Losartan in Primary Hypertension

Boehringer Ingelheim330 enrolled

Overview

Using Losartan as a comparator, to evaluate the efficacy and safety of telmisartan in the treatment of the mild to moderate primary hypertension patients in China

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

330

Conditions

Hypertension

Interventions

Low dose of telmisartanDRUG

High dose of telmisartanDRUG

Low dose of losartanDRUG

High dose of losartanDRUG

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: \- Mild to moderate primary hypertension, the mean sitting valley value of diastolic blood pressure (DBP) ≥ 95 and \< 110 mmHg, and the mean sitting valley value of systolic blood pressure (SBP) \< 180 mmHg Exclusion Criteria: \- Not specified

Outcomes

Primary Outcomes

Changes in mean sitting valley value of DBP

The valley value of blood pressure refers to the blood pressure measured prior to the next administration of antihypertensives

Time frame: 8 weeks after start of treatment

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.